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ABSTRACT Recurrence of meningitis due to Cryptococcus neoformans after treatment causes substantial
mortality in HIV/AIDS patients across sub-Saharan Africa. In order to determine whether recurrence oc-
curred due to relapse of the original infecting isolate or reinfection with a different isolate weeks or months
after initial treatment, we used whole-genome sequencing (WGS) to assess the genetic basis of infection in
17 HIV-infected individuals with recurrent cryptococcal meningitis (CM). Comparisons revealed a clonal
relationship for 15 pairs of isolates recovered before and after recurrence showing relapse of the original
infection. The two remaining pairs showed high levels of genetic heterogeneity; in one pair we found this to
be a result of infection by mixed genotypes, while the second was a result of nonsense mutations in the
gene encoding the DNA mismatch repair proteinsMSH2,MSH5, and RAD5. These nonsense mutations led
to a hypermutator state, leading to dramatically elevated rates of synonymous and nonsynonymous sub-
stitutions. Hypermutator phenotypes owing to nonsense mutations in these genes have not previously been
reported in C. neoformans, and represent a novel pathway for rapid within-host adaptation and evolution of
resistance to ﬁrst-line antifungal drugs.
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The HIV/AIDS pandemic has led to a large population of profoundly
immunocompromised individuals that are vulnerable to infectionby the
opportunistic fungus pathogen Cryptococcus neoformans (Hagen et al.
2015). This mycosis poses a considerable public health problem in sub-
Saharan Africa, which has the highest estimated annual incidence of
CMglobally (Park et al. 2009), with themajority of infections caused by
C. neoformans sensu stricto (previously referred to asC. neoformans var.
grubii) (Jarvis and Harrison 2007).
Standard treatment for HIV-associated CM includes the long-term
use of azole drugs such as ﬂuconazole (FLC), following initial 1–2 wk
induction treatment with amphotericin B, which is often not avail-
able (Brouwer et al. 2004). Microevolution occurs in response to
drug pressure, leading to resistance, a phenomenon previously de-
scribed in C. neoformans (Ormerod et al. 2013; Sionov et al. 2010).
Patients who appear successfully treated [evidenced by symptom
resolution and sterilization of cerebral spinal ﬂuid (CSF)] can re-
lapse due to persisting infections, which in some cases appear to
have evolved resistance to ﬁrst-line antifungal drugs. In the absence
of continued antifungal therapy and restoration of their immune
system through antiretroviral therapy (ART), patients with HIV/
AIDS also have a high probability of recurrence of CM (Bozzette
et al. 1991).
Variousmethods ofwithin-host evolution are available to eukaryotic
pathogens, most notably sexual and parasexual reproduction, although
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these are difﬁcult to observe due to the often cryptic nature of recom-
bination of fungi. Aneuploidy, recombination in the telomeres, and
mutator states (Rodero et al. 2003) also provide means of rapid
within-host evolution, with other mechanisms still likely to be discov-
ered. The accumulation of single nucleotide polymorphisms (SNPs)
alongside copy number variation (CNV) and aneuploidy has been
witnessed during infection in different fungal pathogen species, en-
abling rapid adaptive evolution (Calo et al. 2013) and conferring re-
sistance to antifungal drugs (Hickman et al. 2015). Candidiasis is
caused by numerous Candida species, yet within-host evolution among
these species differs. Infectious strains of Candida albicans are usually
susceptible to azole antifungal drugs, but resistance can evolve via the
evolution of drug-resistant aneuploid isolates, which contain an iso-
chromosome of the left arm of chromosome 5 (Selmecki et al. 2009).
The left arm of chromosome 5 contains two important genes involved
in resistance to antifungals: ERG11, a target of azoles, and TAC1, a
transcription factor that activates drug efﬂux pump expression. Con-
versely,Ca. glabrata strains are intrinsically poorly susceptible to azoles,
and have more recently evolved multi-drug resistance to both azoles
and echinocandins (Pfaller 2012; Panackal et al. 2006; Alexander et al.
2013).
The occurrence ofwithin-host diversity and recombinationhas been
witnessed in eukaryotic pathogens, notably Ca. albicans: mutation and
recombination rates can be increased under stressful conditions, such
as drug treatment (Forche et al. 2009; Ford et al. 2015), resulting in
loss-of-heterozygosity (LOH) and aneuploidy (Forche et al. 2009).
These genetic alterations contribute to the maintenance of a pop-
ulation of Ca. albicans within the host environment (Forche et al.
2009), and drug pressure can result in diverging levels of ﬁtness
(Cowen et al. 2001).
Similar responses to antifungal drugs have been observed in C.
neoformans; point mutations in the ortholog ERG11 were also shown
to confer FLC resistance, by causing the amino acid substitution G484S
(Rodero et al. 2003). Sionov et al. (2010) demonstrated that large-scale
chromosomal duplications (primarily chromosome 1) are fundamental
to overcoming FLC drug pressure in a mouse model, contributing to
failure of FLC therapy. The duplication of chromosome 1 included
increased copy number of genes ERG11, the target of FLC, and
AFR1, a transporter of azoles (Sionov et al. 2010), although other genes
are also thought to be involved in FLC resistance (Sionov et al. 2013;
Paul et al. 2015). Previous studies of serially collected C. neoformans
isolates have conﬁrmed in-host microevolution, including the occur-
rence of large-scale genomic rearrangements (Fraser et al. 2005; Blasi
et al. 2001; Illnait-Zaragozi et al. 2010). Like Ca. albicans, the C. neo-
formans genome is capable of undergoing chromosomal duplication
and loss under stresses such as drug pressure or invasion of the human
host (Fries et al. 1996). These chromosomal duplications are often lost
when the selective pressure is removed (Sionov et al. 2010).
The development of mutator states via hypermutability is a rapidly
expanding area of study in bacteria, particularly Pseudomonas aerugi-
nosa in cystic ﬁbrosis patients. Here, hypermutability has been shown
to have an association with antimicrobial resistance (Oliver et al. 2000;
Maciá et al. 2005), causing signiﬁcant implications in the early treat-
ment of cystic ﬁbrosis patients to prevent chronic infection (Burns et al.
2001; Maciá et al. 2005). Few studies have explored hypermutation in
pathogenic fungi; however, mutations in the yeast Saccharomyces cer-
evisiae genes PMS1, MLH1, and MSH2, which are all involved in mis-
match repair, have been shown to lead to 100–700-fold increases in
mutations throughout the genome (Strand et al. 1993). Frameshift
mutations in an ortholog of the mismatch repair geneMSH2 have also
been shown to contribute to microevolution in the sister species of C.
neoformans, C. gattii (Billmyre et al. 2014).
Here, we describe a comparative genome sequencing-based ap-
proach to investigate microevolution in serially collected isolates of
C. neoformans. These isolates were grown and stored from fresh CSF of
patients with CM, prior to starting and during antifungal therapy using
induction with amphotericin B-based regimens, followed by FLC. We
used WGS to describe the nature of infection in 17 patients to gain
insights into the dynamics of recurrent infections.
MATERIALS AND METHODS
Samples and patients
Sixteen SouthAfrican patients and oneUgandan patient demonstrating
clinical evidence of CM were studied. All patients were either part of
observational studies or clinical trials (Bicanic et al. 2007, 2008; Jarvis
et al. 2010, 2012; Longley et al. 2008). Ethical approval was obtained
from the Wandsworth Research Ethics Committee covering St.
George’s University of London (Longley et al. 2008; Bicanic et al.
2007, 2008; Jarvis et al. 2012). In South Africa, additional ethical ap-
proval was obtained from the University of Cape Town Research Ethics
Committee; in Uganda, from the Research Ethics Committee of Mbar-
ara University of Science and Technology. All patients initially pre-
sented with CM and were treated using induction therapy with 7–
14 d amphotericin B deoxycholate 0.7–1 mg/kg/d, with or without
100 mg/kg/d of ﬂucytosine (with one patient, IFNR63, also receiving
adjunctive interferon g), followed by FLC consolidation at 400mg/d for
8 wk and maintenance therapy at 200 mg/d for 6–12 months
(n = 16 pairs), until immune restoration on ART with a CD4 count
of . 200 cells/ml. The single patient in Uganda received induction
therapy with FLC 1600 mg/d for 2 wk followed by FLC consolidation
and maintenance and ART, as above (n = 1 pair). As part of the study
procedure, patients enrolled in clinical trials had quantitative crypto-
coccal cultures performed on serial CSF samples. Patients with a re-
currence of their cryptococcal disease following initial treatment and
positive CSF culture for Cryptococcus at the time of disease recurrence
were included in the study.We studied the clinical cryptococcal isolates
taken on initial diagnosis (prior to initiation of treatment) and com-
pared each with the Cryptococcus isolated from CSF on recurrence of
disease in the same patient (Table 1).
Multi-locus sequence typing
To discern whether mixed or single genotype infections were extracted
fromCSF,multi-locus sequence typing (MLST)was performedon three
independent colonies for a subset of the study isolates, according to the
methods outlines in Meyer et al. (2009), with modiﬁcations as outlined
in Beale et al. (2015).
Copyright © 2017 Rhodes et al.
doi: https://doi.org/10.1534/g3.116.037499
Manuscript received November 15, 2016; accepted for publication February 3,
2017; published Early Online February 10, 2017.
This is an open-access article distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Supplemental material is available online at www.g3journal.org/lookup/suppl/
doi:10.1534/g3.116.037499/-/DC1.
1Corresponding authors: Department of Infectious Disease Epidemiology, Imperial
College London, VC3, Norfolk Place, London W2 1PG, United Kingdom. E-mail:
matthew.ﬁsher@imperial.ac.uk; and Institute of Infection and Immunity, St.
George’s University London, Cranmer Terrace, London SW17 0RE, United
Kingdom. E-mail: tbicanic@sgul.ac.uk
1166 | J. Rhodes et al.
Molecular methods
C. neoformans was isolated from HIV-infected individuals on location
by plating CSF onto Sabourand Dextrose (SD) agar (Oxoid, Fisher
Scientiﬁc), and growing at 30 for 48 hr. A representative sample of
theC. neoformans population was taken by selecting a broad “sweep” of
all colonies on the SD agar plate, which was stored in cryopreservative
medium (80% SD broth, 20% glycerol) at 280 until further testing.
This approach ensures that all genetic diversity is maintained through
the process, and single colony picking only occurs at the ﬁnal stage of
liquid culture and DNA extraction.
Frozen stocks were plated onto SD agar and cultured for 72 hr. A
single colony was inoculated into 6 ml Yeast Peptone Digest broth
(Oxoid) supplemented with 0.5 M NaCl and cultured at 37 with
agitation (165 rpm) for 40 hr, followed by genomic DNA extraction
using the Masterpure Yeast DNA puriﬁcation kit (Epicentre) modiﬁed
by addition of two cycles of rapid bead beating (45 sec at 4.5 m/sec)
using a FastPrep 24 homogenizer (MP Bio). Genomic DNA libraries
were prepared using the TruSeq DNA v2 or TruSeq Nano DNA kit
(Illumina), and WGS was performed on an Illumina HiSequation
2500 at theMedical Research Council Clinical Genomics Centre (Imperial
College London) as previously described (Rhodes et al. 2014).
WGS analysis
Raw Illumina readswere aligned to theC. neoformans reference genome
H99 (Loftus et al. 2005) using the Burrows–Wheeler Aligner (BWA)
v0.75a mem algorithm (Li 2013) with default parameters to obtain high
depth alignments (average 104 ·). Samtools (Li et al. 2009) version 1.2
was used to sort and index resulting BAM ﬁles, and generate statistics
regarding the quality of alignment. Picard version 1.72 was used to
identify duplicate reads and assign correct read groups to BAM ﬁles.
Furthermore, BAM ﬁles were locally realigned around insertions and
deletions (INDELs) using GATK (McKenna et al. 2010) version 3.4-46
“RealignerTargetCreator” and “IndelRealigner,” following best practice
guidelines (Van der Auwera et al. 2013).
SNPs and INDELs were called from all alignments using GATK
(McKenna et al. 2010) version 3.4-46 “HaplotypeCaller” in haploid
mode, with a requirement that all variants called and emitted were
above a phred-scale conﬁdence threshold of 30. Both SNPs and
INDELs were hard ﬁltered due to a lack of training sets available for
C. neoformans by running VariantFiltration with parameters “DP ,
5 || MQ, 40.0 || QD, 2.0 || FS. 60.0”; this expression ensured that
low-conﬁdence variants were ﬁltered out if theymet just one of the ﬁlter
expression criteria. Resulting high-conﬁdence variants were mapped to
n Table 1 Details of C. neoformans isolates and MICs (if available) at time of isolation from South Africa and Uganda (pair 7 only) used in
this study
Pair # Isolate ID Day of Isolation FLC MIC at Isolation Treatment of CM Episode (if Known)
1 CCTP27 1 4 AmB 3 d
1 CCTP27-d121 121 64 VOR until CD4 . 200 cells/ml
2 CCTP32 1 4 AmB 7 d
2 CCTP32-d132 132 6 AmB 7 d
3 CCTP50 1 16 AmB 14 d
3 CCTP50-d257 257 256 AmB 14 d
3 CCTP50-d409 409 N/A AmB 7 d
4 CCTP52 1 N/A FLC 400 mg/d
4 CCTP52-d55 55 N/A FLC 400 mg/d
5 RCT9 1 2 AmB 0.7 mg/kg/d plus 5FC for 14 d
5 RCT9-d99 99 N/A AmB until death
6 RCT24 1 4 AmB plus 5FC for 14 d
6 RCT24-d154 154 12 FLC 800 mg/d
7 1600-1 1 N/A FLC 16,000 mg/d for 14 d
7 1600-1-d106 106 N/A
8 IFNR63 1 N/A AmB plus 5FC
8 IFNR63-d128 128 N/A
9 IFNR24 1 N/A AmB 7 d
9 IFNR24-d101 101 N/A
10 IFNR18 1 N/A AmB 7 d
10 IFNR18-d134 134 N/A
11 IFNR14 1 N/A AmB 7 d
11 IFNR14-d97 97 N/A
12 IFNR13 1 N/A AmB 7 d
12 IFNR13-d95 95 1
13 IFNR6 1 N/A AmB 7 d
13 IFNR6-d73 73 1
14 IFNR19 1 N/A AmB 7 d
14 IFNR19-d111 111 N/A
15 IFNR11 1 N/A AmB 7 d
15 IFNR11-d203 203 12
16 IFNR27 1 N/A AmB 7 d
16 IFNR27-d204 204 N/A
17 IFNR23 1 N/A AmB 7 d
17 IFNR23-d179 179 N/A
ID, identiﬁer; FLC, ﬂuconazole; MIC, minimum inhibitory concentration; CM, cryptococcal meningitis; AmB, amphotericin B 1 mg/kg/d (as per hospital guidelines at
that time, unless otherwise stated); VOR, voriconazole 300 mg/d; N/A, not applicable; 5FC, ﬂucytosine.
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genes using VCF-annotator (Broad Institute, Cambridge, MA) and the
latest release (CNA3) of the C. neoformans reference genome H99 and
gene ontology (GO).
Some isolates were suspected of having nonhaploid genomes due to
the high number of low-conﬁdence variants. For these isolates,
“HaplotypeCaller” was repeated in diploid mode.
The average (mean) coverage for each isolate were determined using
GATK (McKenna et al. 2010) version 3.4-46 “DepthOfCoverage” un-
der default settings. The C. neoformans H99 (Loftus et al. 2005) was
again used as reference. In order to determine aneuploidy, whole-
genome coverage data were normalized and regions displaying nor-
malized coverage equal to two were deemed diploid events (likewise,
normalized coverage equal to three was deemed a triploid event, and
so on), whereas normalized coverage equal to zero was deemed a
deletion event.
Susceptibility testing
The susceptibility testing of all relapse isolates was performed with the
MICRONAUT-AM susceptibility testing system for yeast (Merlin) as
recommended by the manufacturer. MICRONAUT-AM allows the
determination of MICs of amphotericin B, ﬂucytosine, FLC, voricona-
zole, posaconazole, itraconazole, micafungin, anidulafungin, and cas-
pofungin, and commercializes the well-established, but laborious, CLSI
broth microdilution technique. Brieﬂy, for each isolate, ﬁve colonies
were used to prepare a 0.5 McFarland-standard suspension in 0.9%
NaCl. A 1:20 dilution was prepared in 0.9%NaCl and a 1:5 dilution was
prepared in 11 ml RPMI broth provided with the kit. Next, 100 ml AST
indicator and 50ml methylene blue solutionsweremixedwith the broth
for manual susceptibility testing. The broth was then inoculated onto
Merlin MICRONAUT 96-well testing plates (100 ml/well) and incu-
bated at 30 for 72 hr. The lowest concentration of an antifungal agent
with no detectable growth (MIC) was determined for each isolate based
on fungal growth (pink) or no growth (blue). Obtained MICs were
interpreted according to Ca. albicans EUCAST (Vers. 7.0/12-08-
2014) values (Rodríguez-Tudela et al. 2010; Alastruey-Izquierdo and
Cuenca-Estrella 2012).
Phylogenetic analysis
Whole-genome SNPs were converted into relaxed interleaved Phylip
format. Rapid bootstrap phylogenetic analysis using 500 bootstrap
replicates was carried out on 62 isolates in total (Table 1) using
RAxML-HPC version 7.3.0 (Stamatakis 2006) as described in
Abdolrasouli et al. (2015): 35 isolates from this study in addition to
27 isolates (“nonstudy”) were included to show the phylogenetic con-
text of true relapse infections. These nonstudy isolates, while from a
clinical source, were not recurrent isolates and were not isolated as part
of the clinical trials described in the earlier Materials and Methods
section. Resulting phylogenies were visualized in FigTree version
1.4.2 (http://tree.bio.ed.ac.uk/software/ﬁgtree/). The same process was
completed for each chromosome individually for all 62 isolates, using
250 replicates in the rapid bootstrap analysis.
GO and KEGG pathway analysis
Nonsynonymous SNP (nsSNP)mutations unique to each timepoint for
each pair were assessed for signiﬁcantly overrepresented GO annota-
tions and metabolic pathways. Brieﬂy, genes found to contain a nsSNP
mutation were interrogated for overrepresented Biological Process
Ontology in the C. neoformans H99 database. GO terms that were
found to be associated with genes mapping to the InterPro domain
database were transferred to GO associations, using a P-value cut-off of
P , 0.05. For metabolic pathway enrichment in genes containing
nsSNPs, genes were interrogated against the KEGG (Kanehisa et al.
2016) pathway source forC. neoformansH99, using a P-value cut-off of
P , 0.05.
Identifying sites under selection
BayeScan 2.01 (Foll and Gaggiotti 2008) uses an outlier approach to
identify candidate loci under natural selection. The method uses the
allele frequencies that are characteristic of each population and esti-
mates the posterior probabilities of a given locus under a model that
includes selection and a neutral model. The program then determines
whether the model that includes selection better ﬁts the data. This
approach allows the simultaneous assessment of the inﬂuence of both
balancing and purifying selection. Loci under balancing selection will
present low FST values whereas high FST values reﬂect patterns of local
adaptation (purifying selection) (Excofﬁer et al. 2009). Analysis was not
undertaken for the VNII and VNB lineages due to low numbers of
isolates, which would be insufﬁcient to overcome the strong population
structure. VNI isolates at day 0 were assigned to a population and their
associated relapse isolates constituted the second population. Analyses
were conducted using the standard parameters including a 50,000 burn
in period and 100,000 iterations. Several analyses were conducted vary-
ing the prior odds (from 10 or 100 to 1000) for the neutral model.
Data availability
All raw reads and information on lineages of isolates in this study have
been submitted to the European Nucleotide Archive under the project
accession PRJEB11842.
RESULTS
Clinical and demographic information
The study includedpaired isolates from17patients,with amedian ageof
32 yr (IQR 26–36) and median CD4 count at CM diagnosis of 22 (IQR
9–71) cells/ml. Six patientsweremale, ninewere female, with the gender
of two patients unrecorded. The median time between initial and re-
currence isolates was 115 d (minimum 55 d and maximum 409 d). In
those for whom ART status was known, 2 of 16 (13%) patients were
already on ART at the initial CM episode; 6 out of 15 (40%) patients
had not started ART prior to CM recurrence.
Detailed clinical noteswere available for the recurrentCMepisode in
sevenpatients: two (CCTP52andRCT9)hadnot attended followupand
never started ART prior to admission with recurrence; both died of the
recurrent CM.One patient (CCTP32) had not been taking FLC for 2wk
prior to recurrence. Four patients (CCTP27, CCTP50, RCT24, and
IFNR63) who were adherent to both ART and FLC at recurrence were
assessed ashavingCMimmune reconstitution inﬂammatory syndrome.
Sequencing of paired samples isolated from patients
infected with C. neoformans
Prior to sequencing,multiple colonies from a subset of isolates included
in this study were analyzed usingMLST to investigate whether a mixed
infection was present in the original CSF extract. The results show that
mixed infections were not present in 12 out of 17 pairs included in this
study. One pair (pair 7) was only tested once, and allele types were not
sufﬁcient toconcludewhether sequencetype (ST)100or196waspresent
in both original and recurrent isolate. On two separate attempts, STs for
pairs 3 and 17 could not be determined, reﬂecting a need for WGS to
characterize these pairs. STs for pairs 1 and 6 were inconclusive, and
suggestive of a mixed infection being present.
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Werecoveredanaverage of 23.9million reads fromeach isolate, with
anaverage of 98.8%of readsmapped to theC.neoformansH99reference
genome (Loftus et al. 2005), and an average coverage of 1046 31.2 SD.
To enable comparative studies and detect microevolutionary changes,
precise variant-calling was needed; variants were identiﬁed and false
positive low-conﬁdence variants were ﬁltered out to provide a set of
high-conﬁdence SNPs (see Materials and Methods). Full alignment,
coverage, and variant calling statistics are provided in Supplemental
Material, Table S5 in File S1.
Due to a high number of low-conﬁdence SNPs ﬁltered out in some
isolates, which is suggestive of heterozygous SNPs, variant calling was
rerun in diploid mode (see Materials and Methods) for all isolates in
pairs 3, 4, 5, and 17 (results in Table S6 in File S1).
A high level of diversity was observed within the VNB lineage,
resulting in long branch lengths among isolates within this clade (Figure
1). Although all VNB isolates were mapped to the C. neoformans H99
reference (Loftus et al. 2005), which is a VNI lineage isolate, we do not
believe that SNP numbers observed in the VNB lineage are inﬂated by
the large phylogenetic distance to the reference genome. This is because
SNP determination revealed only 21.6% of SNPs that we discovered
were shared by the three VNB pairs included in this study (pairs 3, 12,
and 17), highlighting the large amounts of genetic diversity seen within
this lineage as we have previously noted (58).
Phylogenetic analysis showed that, of the 17 pairs of relapse isolates,
three pairs were lineage VNB, while four and ten belonged to lineages
VNII and VNI, respectively (Figure 1). The average pairwise SNP di-
versity was far higher among isolates from the VNB lineage (140,835
SNPs) compared to isolates in the VNI (17,808 SNPs) and VNII
(938 SNPs) lineages, showing that the VNI and VNII lineages are less
diverse than VNB across our cohort. On average, isolates of the VNB,
VNII, and VNI lineages accumulated 365, 12, and 3 unique SNPs per
day between the time of the original isolation and the recurrence of
infection. Isolates in the VNB lineage were more likely to experience a
ploidy event, with an average of 1.6 changes in ploidy per isolate. Less
than one isolate in the VNII and VNI lineages would, on average,
experience ploidy events (0.375 and 0.26, respectively).
All pairs, with the exception of pair 7, were isolated from patients in
SouthAfrica; pair 7 was isolated from a patient inUganda.We classiﬁed
the second isolate as a relapse of the original infection if. 97% of SNPs
were in common between original and recurrent isolates. The majority
of pairs had . 99% SNP similarity (Table 2) between original and
recurrent isolates, with Pairs 6, 7, and 14 displaying 97, 98, and 97%
similarity, respectively. Therefore, all pairs, with the exception of pairs
3 and 17 (SNP similarity 44 and 56%), could be classiﬁed as relapsed
infections on this basis. This conﬁrms previous results obtained by
MLST, and that the original and recurrent isolates sequenced from
pairs 1 and 7 (which had previously indicated a potentially mixed in-
fection) were indeed true relapse infections.
Within the VNB pairs (3, 12, and 17), the accumulation of SNPs
between original and recurrent infection varied widely. We observed
178 and 304 SNPs/d for CCTP50-d257 and CCTP50-d409, respectively
(pair 3), 8 SNPs/d for pair 12, and 968 SNPs/d for pair 17. Due to the
variation in SNP accumulation between pair 12 and pairs 3 and 17, we
hypothesized that pair 12 was a true relapse of the original infection,
while pairs 3 and 17 were showing inﬂated SNP numbers due to
reinfection or an anomalous rate of evolution.
Antifungal susceptibility testing
FLC susceptibility testing (Table 1) using the Etest (bioMerieux) was
carried out for 12 isolates (including three paired isolates) in this study
by the accredited central Microbiology laboratory in Cape Town at the
time of the clinical episode; ﬁve of these (CCTP27-d121 in pair 1;
CCTP50 and CCTP50-d257 in pair 3; RCT24-d154 in pair 6; and
IFNR11-d203 in pair 15) had MICs above the established epidemio-
logical cut-off value ($ 8 mg/ml) for FLC. All pairs were retested fol-
lowing 5–10 yr frozen storage in glycerol using the MICRONAUT-AM
system for yeast susceptibility (Materials and Methods): all were
found to be sensitive to FLC.
The fourfold increase in FLC MIC observed in pairs 1 and 3 initial
and recurrent infections provide a sound basis for relapse of infection
due todrug resistance: inpair1 (patientCCTP27), the initial isolatehada
susceptible FLC MIC of 4 mg/ml, while the recurrent isolate was re-
sistant at aMIC of 64mg/ml; in pair 3 (CCTP50), the initial isolateMIC
was 16mg/ml (intermediate), while a highly resistantMIC of 256mg/ml
was found on recurrence at day 257.
Serial isolates share a recent common ancestor,
suggesting relapse of infection
To investigate whether the C. neoformans isolates from the same pa-
tients were relapse infections of the original isolates or infections with a
new isolate, we undertook phylogenetic analyses to determine their
relationships.
As described above, the high level of common SNPs and subsequent
low level of unique SNPs between recurrent isolates indicated that all
pairs, with the exception of pairs 3 and 17, were relapses of the original
infections (Table 2). Phylogenetic analysis (Figure 1) conﬁrmed that all
pairs (excepting pairs 3 and 17) clustered together with short branch
lengths, conﬁrming the low level of divergence between original and
recurrent isolates, thus conﬁrming that they were relapses of the orig-
inal infections. However, only 46 and 56% of SNPs were found to be in
common between initial and relapse infections in pairs 3 and 17, re-
spectively (Figure 1 and Table 2). These VNB pairs (pair 3: CCTP50,
CCTP50-d257, and CCTP50-d409 and pair 17: IFNR23 and IFNR23-
d179) showed markedly longer branch lengths, suggesting either re-
infection or elevated rates of within-host evolution. Further analysis
was undertaken to conﬁrm or refute that reinfection by a different
isolate was responsible for pairs 3 and 17. Phylogenetic analysis for
all isolates included in Figure 1 was repeated for each of the 14 C.
neoformans chromosomes individually (Figure S1).
Phylogenetic analysis of pair 3 showed that the original infecting
genotype of CCTP50 was highly related to the isolate IFN26 (not
included in this study but included in the phylogeny to assist with
deﬁning lineages, seeMaterials andMethods). All three genotypes from
pair 3 were found to be phylogenetically clustered together, but with
long branches (Figure 1). Chromosome-by-chromosome analysis in-
dicated that pair 3 serially isolated genotypes displayed differing rela-
tionships for each chromosome, and all three serial genotypes were
clustered together only in the phylogeny for chromosome 1 (Figure
S1). All three genotypes were phylogenetically similar for three other
chromosomes, however long branches and clustering with additional
nonstudy isolates suggested differing evolutionary relationships. The
three serially isolated genotypes of pair 3 were completely phylogenet-
ically dissimilar in three chromosomes; the remaining chromosomes
saw either the day 1 isolate (CCTP50) and day 409 isolate (CCTP50-
d409), or the day 257 isolate (CCTP50-d257) and day 409 isolate
(CCTP50-d409) phylogenetically more related.
Pair 17 isolates (ID IFNR23) clustered together in only two of the
14chromosomal phylogenies explored (chromosomes 10and12); in the
remaining chromosomal phylogenies, the pair 17 isolates either dis-
played a close phylogenetic relationship but with long branches (six
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chromosomes), or were phylogenetically distinct from one another and
were more phylogenetically related with other study or additional
isolates (six chromosomes).
Microevolution within the human host
Our data present a unique opportunity to observe microevolution of all
three lineages of C. neoformans in the human host. Although multiple
factors determine evolutionary rates, identifying nsSNPs that cause
amino acid change is a standard method for inferring genetic diversity
and observing natural selection on codons.
Less than 3%of nsSNPswere unique to recurrent isolates in all pairs,
further suggesting that all pairs are relapse of the original infection, with
theexceptionof theVNBpairs3and17(15.2and59.8%ofallnsSNPsare
unique, respectively).
SNPsunique toeachtimepoint foreachpairwere identiﬁed.All SNPs
atday1 inall pairs, andall SNPsat timeof isolateof recurrent infection in
all pairs, were compared. No SNPs were found to be common to all
17 pairs at either day 1 or at point of recurrent infection; however, there
were VNII and VNB lineage-speciﬁc and timepoint-speciﬁc, common
SNPs.
Five SNPs, all intergenic, were found to be common at day 1, along
with ﬁve different SNPs, also intergenic, within VNB pairs (pairs 3, 12,
and 17). Three intergenic SNPs were common to all VNII pairs (pairs 2,
4, 5, and 9) at timepoint day 1, while 14 SNPs were common to all VNII
pairs at the point of recurrent infection, ﬁve of which were intergenic.
The remaining nine SNPs were located in the 59-untranslated region
(UTR) gene SMF1 (CNAG_05640), a metal ion transporter with a
natural resistance-associated macrophage protein. However, selection
analysis indicated that this gene was not under selection pressure.
To evaluate the genetic divergence, Wright’s ﬁxation indexes (FST)
were calculated to identify SNPs under selection in VNI original and
recurrent infection populations investigating 96,856 loci (seeMaterials
and Methods). No putative loci under either diversifying or balancing
selection could be detected using a false discovery rate of 0.05. FST
values were limited to not exceed 3.47 · 1025.
Aneuploidy as a generator of diversity in
recurrent infection
Normalized whole-genome coverage was plotted to observe possible
aneuploidy (increase or decrease in copies of chromosomes Figures 2
and S2) and CNV events. Aneuploidy events were observed in seven
genome pairs, suggesting either interspersed or tandem duplications of
large segments of the genome.
Ormerod et al. (2013) previously published a study showing relapse
isolates exhibiting aneuploidies of chromosome 12. We observed an-
euploidy of chromosome 12 in four pairs (pairs 1, 5, 10, and 14) in-
cluded in this study. The aneuploidy spanned different regions of
chromosome 12 in all pairs, but all aneuploidies were present in the
right arm of the chromosome: in pair 5 the aneuploidy was restricted to
392 kbp of one chromosome arm; in pair 1, the aneuploidy spanned an
Figure 1 Phylogenetic analysis of C. neoformans var. grubii isolates in this study (colored), with additional isolates (shown in black) added to
distinguish true relapse infections, or recurrent infections, and associated lineages. We hypothesize that isolates resulting from true relapse
infections would be closely related phylogenetically. Bootstrap analysis over 500 replicates was performed on WGS SNP data from 62 isolates,
including the 35 isolates included in this study, to generate an unrooted maximum-likelihood phylogeny, with all branches supported to 69% or
higher (with the exception of a particularly clonal VNI clade, including pair 15 only, which only had 47% branch support). Branch lengths represent
the number of SNPs between taxa. SNP, single nucleotide polymorphism; WGS, whole-genome sequencing.
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entire arm of chromosome 12 (603 kbp). Pair 14 displayed this aneu-
ploidy in both the initial and recurrent infection, and the aneuploidy
spanned the whole chromosome; the recurrent infection isolate of pair
10 also displayed aneuploidy along the whole chromosome. Evaluation
of the read depth along chromosome 12 revealed triplication of the
chromosome 12 arm in the Pair 1 recurrent infection isolate, a phe-
nomenon also seen in Ormerod et al. (2013). Further analysis of read
depth in the pair 5 recurrent isolate revealed a diploid genome, and
chromosome 12 was also experiencing triploidy. Current annotation of
the C. neoformans H99 genome reveals the presence of 327 genes in
chromosome 12; the right arm of chromosome 12 has 260 genes pre-
sent. We scanned the genes present in this arm of chromosome 12 for
genes potentially involved in virulence, which might prove advanta-
geous to the progression of infection or drug resistance. One such gene
was SFB2 (CNAG_06093), which is involved in the conservation of the
sterol regulatory element-binding protein pathway (Chang et al. 2009).
An alcohol dehydrogenase (GNO1 – CNAG_06168) was also present,
which is thought to be involved in the defense against host response (de
Jesús-Berríos et al. 2003). Analysis for enrichment of metabolic path-
ways also revealed that the genes present in this chromosome arm are
signiﬁcantly involved in the metabolism of drugs (corrected P-value
P , 3.81e22).
We searched for CNV in genes known to be involved in drug
resistance and virulence. CAP10 appeared to be haploid in all isolates,
with the exception of pairs 4 and 5, where the initial infection
(CCTP52) and recurrent infection (RCT9-d99) were found to be dip-
loid, respectively. However, on closer inspection (see Materials and
Methods), we believe that the isolates in pairs 4 and 5 (CCTP52 and
RCT9-d99) have diploid genomes, implying that the CAP10 gene is
actually tetraploid. Whether the remaining isolates in these two pairs
(CCTP52-d55 and RCT9) have diploid genomes could not be distin-
guished; however, it is clear that CAP10 loses ploidy from initial in-
fection to relapse for pair 4, with no evidence of LOH, while the reverse
is true for pair 5.CAP10was also found to be tetraploid (as the genomes
of these isolates were found to be diploid) in both initial and recurrent
infections for pairs 3 and 17.
The ERG11 gene on chromosome 1 was found to have increased
copy number in numerous pairs (2, 3, 4, 5, 9, 12, and 17), and was not
found to be lineage-associated. However, this CNV was maintained
throughout infection to recurrence in all pairs, with the exception of
pair 4; since pair 4 initial infection (CCTP52) was found to have a
diploid genome, ERG11was tetraploid, and lost this ploidy to be diploid
with respect to the rest of the genome in the recurrent infection
(CCTP52-d55). While chromosome 1 was duplicated in the initial in-
fection isolate of pair 15 (IFNR11), ERG11was found to be haploid; the
ploidy of the chromosome was subsequently lost in the recurrent in-
fection isolate of pair 15 (IFNR11-d203).
ERG11 in pair 4 (ID CCTP52) did not have any nsSNPs in the
original infection (CCTP52), but one nsSNP was present in ERG11
in the recurrent infection (CCTP52-d55). Clinical notes show that
the patient from which pair 4 was isolated was given FLC (400 mg/d)
on initial infection, did not attend follow up or receive ART or further
FLC, and was then readmitted and died from CM recurrence at day 55.
MIC values were unfortunately not available for either original or re-
current isolates.
Nonsense mutations in DNA mismatch repair genes
cause hypermutator states
Phylogenetic analysis on a chromosome-by-chromosomebasis revealed
that pair 3 isolates only clustered together in two of the fourteen
chromosomes; the three isolates were phylogenetically dissimilar in
four chromosomes,whileday257 and409 isolates (pair 3CCTP50-d257
and CCTP50-d409) were phylogenetically more similar to each other
than to the day 1 isolate (CCTP50) in ﬁve chromosomes. Day 1 and day
409 isolates were more phylogenetically similar than to the day 257 iso-
late in three chromosomes.The lackof phylogenetic similarity (12 out of
14 chromosomes) shown in the three isolates of pair 3 indicated that
these three isolates donot showa recent commonancestor, andprovides
evidence for reinfection with a new isolate, rather than relapse. In
contrast, the two isolates in pair 17 were only phylogenetically related
for ﬁve out of the 14 chromosomes (Figure S1), suggesting that on this
basis the recurrent infection was distinct enough as to be deﬁned as a
nonrelapse infection in this pair. However, on further investigation this
was found not to be the case.
We analyzed the coverage proﬁles and synonymous/nonsynony-
mous ratios of both isolates in pair 17 (Figure 2C). Although the
n Table 2 A high number of shared SNPs in most pairs indicate a shared common ancestor
Pair
Common
SNPs
(% Total)
Day 1
SNPs
(% Total)
No. Day 1
nsSNPs
(Genes Mapped)
Relapse
SNPs
(% Total)
No. Relapse
nsSNPs
(Genes Mapped)
Relapse #2
SNPs
(% Total)
No. Relapse
#2 nsSNPs
(Genes Mapped)
1 13,490 (98.49) 97 (0.71) 9 (8) 110 (0.81) 19 (8)
2 289,557 (99.29) 1,080 (0.37) 110 (55) 991 (0.34) 108 (45)
3 261,718 (46.77) 127,631 (32.78) 25,331 (2,741) 45,769 (14.88) 8,342 (2,099) 124,498 (32.24) 23,957 (2,541)
4 289,574 (99.22) 1,169 (0.40) 145 (58) 1,096 (0.38) 145 (56)
5 289,367 (99.20) 1,261 (0.43) 127 (54) 1,080 (0.37) 127 (59)
6 13,122 (95.78) 133 (1.00) 5 (2) 445 (3.28) 82 (56)
7 47,833 (97.83) 522 (1.08) 81 (65) 537 (1.11) 94 (72)
8 46,883 (98.76) 294 (0.62) 29 (9) 296 (0.63) 26 (16)
9 289,458 (99.27) 1,033 (0.36) 141 (58) 1,109 (0.38) 105 (55)
10 12,687 (98.29) 104 (0.81) 4 (3) 117 (0.91) 11 (5)
11 12,732 (98.38) 110 (0.86) 10 (2) 99 (0.77) 6 (5)
12 221,973 (99.37) 636 (0.29) 55 (27) 778 (0.35) 61 (30)
13 48,062 (98.58) 396 (0.82) 31 (11) 294 (0.61) 28 (15)
14 28,960 (95.66) 288 (0.98) 44 (19) 1,026 (3.42) 105 (57)
15 29,736 (98.40) 254 (0.85) 21 (14) 228 (0.76) 17 (13)
16 45,437 (98.56) 325 (0.71) 30 (18) 341 (0.74) 30 (14)
17 376,568 (56.43) 117,436 (23.77) 22,567 (4,153) 173,359 (31.52) 33,543 (4,427)
Number of SNPs common to both initial and recurrent infection, along with number of SNPs and nonsynonymous SNPs unique to each timepoint. Percentages given
to 2 d.p. SNP, single nucleotide polymorphism; No., number; nsSNP, nonsynonymous SNP.
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aneuploidies observed were extensive throughout the genome, the in-
creases in ploidy appeared on similar chromosomes in both isolates. A
similar observation was seen for the strikingly increased number of
nsSNPs in both isolates in pair 17: 41,549 and 46,622 nsSNPs for
IFNR23 and IFNR23-d179, respectively; an even larger increase in
synonymous SNPs was also observed (68,094 and 82,172 synonymous
SNPs for IFNR23 and IFNR23-d179, respectively). Therefore, we
sought to identify a mechanism responsible for the high number of
synonymous and nsSNPs, and ploidy.
Previous studies have reported thatmutations in theDNAmismatch
repair gene MSH2 have resulted hypermutator effects in bacteria and
the yeast S. cerevisiae (Drotschmann et al. 1999). Both pair 17 isolates
were found to harbor two nonsense (i.e., point mutations in the DNA
sequence that result in a premature stop codon) mutations within the
coding region of the gene encoding MSH2, the DNA mismatch repair
protein. Nonsense mutations inMSH2 were not observed in any other
pairs included in this study. Thesemutations were in the same positions
in both the original and recurrent isolates (Ser-888-STOP and Ser-86-
STOP).
We then performed a genome-wide search in both pair 17 isolates to
identify further nonsense mutations in DNA mismatch repair genes.
Both pair 17 isolates were found to harbor a single nonsense mutation
within the coding regions of genes encoding MSH5 and RAD5. Again,
nonsensemutations in these genes were not observed in any other pairs
included in this study. These nonsense mutations caused Gln-1066-
STOP in RAD5 and Gln-709-STOP in MSH5 in both original and
recurrent isolates.
Since the likelihood of such mutations occurring by chance in
independent genomes lacking a common ancestor is very small, this
suggests that rather than being a reinfection, this was indeed a relapse of
theoriginal infection, and thephylogeneticdissimilaritybetween the two
isolates was due to hypermutation. A total of 293 SNPs were located in
MSH2 in both pair 17 isolates, compared to a mean of 30 SNPs per
isolate in the remaining pairs that we studied (Table S2 in File S1).More
SNPs overall were observed in the recurrent isolate (IFNR23-d179) in
both RAD5 and MSH5 (361 and 357, respectively) when compared to
the original isolate (IFNR23 – 320 for RAD5 and 305 forMSH5). These
numbers are considerably higher than the average of 46 SNPs and
37 SNPs per isolate in the remaining pairs included in this study for
RAD5 and MSH5, respectively.
DISCUSSION
Relapse of CMcaused byC. neoformans is usually due to the persistence
and recurrence of the original infecting isolate (Spitzer et al. 1993), and
studies often focus on rates of within-host microevolution between
serially collected isolates. However, recent studies have shown that an
infection of a population of dissimilar genotypes is responsible for 20%
of relapse cases (Desnos-Ollivier et al. 2010). We used WGS to distin-
guish co-infections of a population of genotypes from a relapse of a
single genotype owing to treatment failure (Figure 3). Using WGS we
can distinguish between relapses of infection of the same genotype,
which differ by only a few SNPs, while initial infection by a population
of dissimilar genotypes will see a difference of many SNPs between
initial and relapse infection as genetic drift occurs. Our results show
that C. neoformans incurs numerous unique small and large-scale
changes during infection, and that a subset of these may have adaptive
value. While this study is concerned with the genomics of recurrent
infections by identifying SNP changes and ploidy potentially involved
in the persistence of C. neoformans infection, future work should
investigate the potential role of gene expression changes and gene
networks involved in changes in ﬁtness among the populations of
infecting genotypes that underpin the recurrence of infection. Previous
studies in Brucella infection and TB have highlighted the merits of
using transcriptomics to identify patients requiring more intensive
treatment (Dufort et al. 2016) and differentiating between dormancy
and reactivation (Kondratieva et al. 2014), respectively. Given the
higher genetic variation observed in the VNB lineage, the genomic data
could also be exploited to investigate genome content variation, as this
is known to be a major determinant in yeast phenotypic variation (56).
Such approaches are likely to increase our understanding of clinical
cases of recurrent C. neoformans infections through identifying the
genetic basis of phenotypic switching (D’Souza and Heitman 2001)
and the gene regulatory networks involved in latency, virulence, and
resistance to antifungal therapies.
Onepair (pair 3) included in this studydidnotdisplay a relapseof the
initial infecting isolate. Analysis of this pair showed that only 46% of
SNPs were in common between the initial and recurrent infection,
suggesting that relapse was caused by a new, albeit similar, genotype.
These co-infection events are rarely reported in the literature; however,
Hagen et al. (2015) did ﬁnd evidence of co-infection in a single patient
using AFLP (58). The extensive chromosomal CNVs, or aneuploidies,
observed in pair 3 (Figure 2) also show that different genotypes were
isolated at subsequent timepoints (days 257 and 409). Phylogenetic
analyses showed that this pair belongs to the VNB lineage; it is known
that a population of VNB genotypes can be found in one location, such
as on the same tree (Vanhove et al. 2016). Therefore, it is possible for a
single immunocompromised individual to inhale a cluster of basidio-
spores from a singlemating population, whichwould lead to a cluster of
related, but recombined, genotypes that then come to dominate the
infection at different timepoints. Although a population can reside in
an environmental reservoir, recombination between genotypes can oc-
cur, generating closely related, yet distinct, genotypes (Figure 3B). This
latter hypothesis supports our observations of differing numbers of
nsSNPs between day 257 (CCTP50-d257) and the original (CCTP50)
and day 409 (CCTP50-d409) isolates, as well as the ploidies and MIC
values (Table 1) seen at the time of sample isolation: the day 1 isolate
(CCTP50) initially had an intermediate FLC MIC of 16 mg/ml, while
the recurrent isolate at day 257 had a highly resistant FLC MIC of
256 mg/ml. These MIC values are suggestive of drug-resistant geno-
types being present and selected for within this patient by the prolonged
maintenance on FLC monotherapy following induction therapy with
amphotericin B. It is also likely that the population of VNB isolates
circulating in the patient were not sufﬁciently sampled by sequencing
only one colony at each timepoint, and that deeper sequencing would
have uncovered greater genomic diversity.
The occurrence of aneuploidy, where an abnormal number of
chromosomes is observed, is seen as an evolutionaryprocess that rapidly
alters ﬁtness, and has been described in multiple human fungal path-
ogens as a means of generating drug resistance (Selmecki et al. 2006;
Sionov et al. 2010). Sionov et al. (2010) reported the duplication of
multiple chromosomes in response to high concentrations of FLC,
which resulted in genotypes developing FLC drug resistance. Associ-
ated gene duplications in C. neoformans chromosome 1 included
ERG11 and AFR1, which are both transporters of azole drugs. While
duplications of ERG11were seen in seven pairs (2, 3, 4, 5, 9, 12, and 17),
these were not necessarily associated with an entire duplication of
chromosome 1. Sionov et al. (2010) suggested that ERG11 contributed
to the duplication of chromosome 1; we observed only one isolate
(IFNR11 of pair 15) displaying a duplication of chromosome 1, but a
single copy of ERG11, suggesting that ploidy was not complete
throughout the chromosome. Since this isolate was the initial infection,
1172 | J. Rhodes et al.
we can assume that the duplication of chromosome 1was not solely due
to the stress of azole drug treatment, suggesting that ploidy can be
activated under different conditions, such as the stress associated with
adaptation to the host. A possible limitation is that the observed du-
plication may be due to prolonged frozen storage.
Ormerod et al. (2013) showed an aneuploidy (duplication) in chro-
mosome 12 between serially collected isolates. Four pairs included in
this study (pairs 1, 5, 10, and 14) all showed aneuploidy in chromosome
12; however, pair 14 (ID IFNR19) displayed this aneuploidy in both the
initial and relapse infections. Since aneuploidies are typically lost upon
removal of drug pressure (Sionov et al. 2010), one can assume that this
aneuploidy was maintained due to previous drug exposure potentially
not being reported by the patient, or that aneuploidy helps C. neofor-
mans adapt to the host environment (Morrow and Fraser 2013). Chro-
mosome 12 experienced triploidy in the pair 1 recurrent isolate
(CCTP27-d121); this pair also demonstrated drug resistance to FLC,
with a FLC MIC of four at initial infection, and a FLC MIC of 64 at
recurrent infection. Ormerod et al. (2013) hypothesize that the large
number of genes affected by the increased copy number of chromo-
some 12 contributes to metabolome differences; however, we hypoth-
esize that CNV of chromosome 12 is a response to FLC stress, resulting
in increased MIC, and that some genes present on chromosome 12,
such as ERG8 andCAP6, may be targets of azole drugs or involved in C.
neoformans virulence.
Antimicrobial drugs impose strong selection pressure on pathogens,
which may lead to the evolution of drug resistance (Mu et al. 2010;
Didelot et al. 2016); there are, however, ﬁtness costs associated with the
evolution of resistance to antifungal drugs that may impact ﬁtness
(Cowen et al. 2001). Genome-wide scans for sites under selection lead
to the identiﬁcation of possible sites of drug resistance. We did not
identify any signiﬁcant sites when comparing VNI original infection vs.
recurrent infection, and the number of VNB andVNII isolates were too
low for analysis. While these results could be interpreted as there being
no sites under selection in the VNI isolates sampled in this study, it is
more likely that similar patterns would not be seen among individuals
due to stochasticity and clonal interference (Didelot et al. 2016). It is
also likely that, as there is little recombination inVNI isolates compared
to VNB and VNII isolates (Khayhan et al. 2013; Litvintseva et al. 2006,
2011), linkage is complete across the genome, further hampering se-
lection analysis. Therefore, we found no evidence for genetically de-
termined alterations in drug resistance in the study isolates.
MICvalueswere only obtained for 9 out of 35 isolates in this study at
the time of sampling. Susceptibility testing at a later date revealed all the
isolates to be susceptible to antifungal drugs including FLC, suggesting
that any resistant phenotypes had been lost in the absence of drug
selective pressure. Therefore, it is very important that clinicians request
susceptibility testing in real time, at the very least in all cases of recurrent
CM.
While pair 17 did not exhibit a high percentage of common SNPs
between the original and recurrent isolates indicative of a relapse
Figure 2 Extensive chromosomal copy number variation was ob-
served in all isolates in pairs 3 and 17, when compared to H99. Pair 2 is
included to illustrate isolates without ploidy and extensive nsSNPs.
Here, normalized whole-genome depth of coverage is shown, aver-
aged over 10,000 bp bins, in scatter plots. Bar plots represent the
position of nsSNPs. The purple track represents the original isolate,
orange the recurrent isolate, and green (in the case of pair 3) for the
ﬁnal recurrent isolate. (A) No increase in ploidy is observed in either
the original or recurrent isolate of Pair 2, and a small number of nsSNPs
are seen. (B) Increase-in-ploidy is observed in many chromosomes in
the day 1 isolate for pair 3, some of which are lost over time. A large
number of nsSNPs are observed in all chromosomes in isolates of pair
3, with Chr 6 being the exception: very few nsSNPs are located in Chr
6 in CCTP50 and CCTP50-d409, whereas over 2000 nsSNPs are
observed in Chr 6 in CCTP50-d257. (C) A gain in ploidy is observed for
Chrs 2, 4, 6, and 9 compared to the day 1 isolate in pair 17, whereas
ploidy remains unchanged for Chr 1 and 12. Chr, chromosome; nsSNP,
nonsynonymous single nucleotide polymorphism.
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infection, the elevated rate of SNPs observed in all chromosomes of
both isolates suggested that this was not a reinfection as seen in pair
3 (Figure 3C). Rather, our results suggest that the isolates in this pair
were exhibiting a hypermutator phenotype, as a result of two nonsense
mutations in the DNAmismatch repair geneMSH2, and one nonsense
mutation in each of the DNAmismatch repair genes RAD5 andMSH5.
While previous studies have shown that hypermutator phenotypes aid
adaptation to stress (Magditch et al. 2012), we hypothesize that hyper-
mutation may lead to adaptation of drug resistance under the stress of
antifungal treatment. These results are, to the authors’ knowledge, the
ﬁrst to report on nonsensemutations inMSH2, RAD5, andMSH5 inC.
neoformans. Further investigation is required to determine whether
these nonsense mutations have a role in drug resistance phenotypes
using transcriptomic approaches and creating single-gene knockout
mutants of MSH2, RAD5, and MSH5. It is also necessary to test the
virulence of hypermutator isolates in the mouse model and to describe
the impact of the increase inmutation rate that occurs as a result of this
hypermutation. Our study only includes one pair of hypermutator
genotypes, so further sampling is required to identify whether this
phenomenon is speciﬁc to the VNB lineage, whether hypermutators
occur in the VNII and VNI lineages, and whether they are clinically
relevant.
This work represents the most extensive comparative genome
sequencing-based study to investigate microevolution in serially col-
lected isolates of C. neoformans to date. The observation of an infection
of a single patient with a population of VNB isolates is clinically rele-
vant, as widely used drug regimens with azolemonotherapymay not be
effective against such a genetically diverse infection. It is also likely that
the extensive genetic diversity seen in clinically isolated VNB isolates
may be due to mixed infection. Hypermutation due to nonsense
Figure 3 Hypotheses of routes
of infection of the human host
by C. neoformans var. grubii. (A)
Inhalation of a single population
of basidiospores into a new
host. Due to low within-host di-
versity and being drug naïve,
there will be a bottleneck in
population size due to antifun-
gal drug treatment. However, if
the initial drug regimen is insuf-
ﬁcient to sterilize the cerebral
spinal ﬂuid, resistance may de-
velop on ﬂuconazole mainte-
nance therapy due to selection
pressure, resulting in relapsed
infection from proliferation of a
drug-resistant isolate. (B) VNB
lineage C. neoformans exists in
the environment as a population
that can undergo recombination
to produce genetically similar
isolates, but with signiﬁcantly di-
versity. Due to transmission bot-
tlenecks, only a sample of the
pathogen diversity will be trans-
ferred to the host, in this case by
inhalation, but it is possible for a
population of C. neoformans to
infect a single immunocompro-
mised individual. Some isolates
may be susceptible to antifungal
drugs and are thus removed,
while other isolates may be in-
herently resistant and hence
cause a relapse infection. (C)
Mutations in the DNA mismatch
repair gene MSH2 cause an iso-
late to become a hypermutator.
Some genotypes may be sus-
ceptible to antifungal drugs,
but the high mutation rate al-
lows the infection to adapt rap-
idly to the host and evolve drug
resistance. These genotype pro-
liferate in the host, thus causing
relapse infection.
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mutations in the DNA mismatch repair genes MSH2, RAD5, and
MSH5 cause an increased mutation and rate of aneuploidy in C. neo-
formans, which may confer an increased ability to adapt to drug pres-
sure. Further sampling is required to identify whether hypermutation is
a phenomenon only observed in the VNB lineage, and how these
mutations impact the ﬁtness of C. neoformans by imposing a high
genetic load.
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